These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18506458)

  • 1. Tumor markers in mature cystic teratomas of the ovary.
    Ustunyurt E; Gungor T; Iskender C; Ustunyurt BO; Bilge U; Mollamahmutoglu L
    Arch Gynecol Obstet; 2009 Feb; 279(2):145-7. PubMed ID: 18506458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
    Kataoka T; Watanabe Y; Hoshiai H
    J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and clinical significance of tumor markers in ovarian mature cystic teratoma.
    Chen JM; Gao HY; Wang Q; Li Q
    Clin Exp Obstet Gynecol; 2016; 43(3):397-400. PubMed ID: 27328499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of multiple tumor marker detection for mature and immature teratoma of the ovary].
    Chen C; Li JD; Huang H; Feng YL; Wang LH; Chen L
    Ai Zheng; 2008 Jan; 27(1):92-5. PubMed ID: 18184473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA19-9 may have clinical significance in mature cystic teratomas of the ovary.
    Dede M; Gungor S; Yenen MC; Alanbay I; Duru NK; Haşimi A
    Int J Gynecol Cancer; 2006; 16(1):189-93. PubMed ID: 16445632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do high levels of CA 19-9 in women with mature cystic teratomas of the ovary warrant further evaluation?
    Ugur MG; Ozturk E; Balat O; Dikensoy E; Teke S; Aydin A
    Eur J Gynaecol Oncol; 2012; 33(2):207-10. PubMed ID: 22611965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of elevated cancer antigen 19-9 in women with mature cystic teratoma.
    Frimer M; Seagle BL; Chudnoff S; Goldberg GL; Shahabi S
    Reprod Sci; 2014 Oct; 21(10):1307-11. PubMed ID: 24577158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated CA 19-9 levels in mature cystic teratoma of the ovary.
    Kyung MS; Choi JS; Hong SH; Kim HS
    Int J Biol Markers; 2009; 24(1):52-6. PubMed ID: 19404923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-stratified analysis of tumor markers and tumor characteristics in adolescents and young women with mature cystic teratoma.
    Yesilyurt H; Seckin B; Aktulay A; Ozyer S
    J Chin Med Assoc; 2018 Jun; 81(6):499-504. PubMed ID: 28826726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma.
    Cho HY; Kim K; Jeon YT; Kim YB; No JH
    Med Sci Monit; 2013 Mar; 19():230-5. PubMed ID: 23539074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of CA19-9 in ovarian mature cystic teratoma.
    Fan JT; Yan HQ; Malla S; Fan YJ; Xu H; Li DH; Liu Y
    Clin Exp Obstet Gynecol; 2016; 43(4):522-525. PubMed ID: 29734540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mature cystic teratomas: relationship between histopathological contents and clinical features.
    Cakmak B; Nacar M; Ozsoy Z; Aliyev N; Koseoglu D
    Niger J Clin Pract; 2015; 18(2):236-9. PubMed ID: 25665999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant simultaneous changes in serum CA19-9 and CA125 due to prolonged torsion of mature cystic teratoma of the ovary.
    Suh DS; Moon SH; Kim SC; Joo JK; Park WY; Kim KH
    World J Surg Oncol; 2014 Nov; 12():353. PubMed ID: 25416055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
    Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
    Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric ovarian neoplastic tumors: incidence, age at presentation, tumor markers and outcome.
    Taskinen S; Fagerholm R; Lohi J; Taskinen M
    Acta Obstet Gynecol Scand; 2015 Apr; 94(4):425-9. PubMed ID: 25640522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian masses in children and adolescents - an analysis of 521 clinical cases.
    Zhang M; Jiang W; Li G; Xu C
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):e73-7. PubMed ID: 24157281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of 44 cases with malignant transformation of ovarian mature cystic teratoma].
    An JS; Wu LY; Li XG; Zhang R; Song Y; Ma SK; Liu LY; Hong WJ
    Zhonghua Fu Chan Ke Za Zhi; 2013 Feb; 48(2):123-8. PubMed ID: 23544494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Giant mature ovarian cystic teratoma including more than 300 teeth.
    Devoize L; Collangettes D; Le Bouëdec G; Mishellany F; Orliaguet T; Dallel R; Baudet-Pommel M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Mar; 105(3):e76-9. PubMed ID: 18280952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.